Uterine leiomyoma: understanding the impact of symptoms on womens’ lives

• Autor(a) principal: Brito, Luiz Gustavo Oliveira
• Data de Publicação: 2014
• Outros Autores: Panobianco, Marislei Sanches, Sabino-de-Freitas, Maurício Mesquita, Barbosa, Hermes de Freitas, Azevedo, George Dantas de, Brito, Luciane Maria Oliveira, Candido-dos-Reis, Francisco José
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/31599
• topic: Uterine leiomyoma; Health related quality of life; Counseling; Qualitative research; Abnormal uterine bleeding; Pelvic pain

Background: most women report negative experience about the symptoms of uterine leiomyoma (UL) in their lives, such as abnormal uterine bleeding and pelvic pain. Many studies have been conducted about efficacy of UL treatment, but little research has been performed about womens health related quality of life (HRQL). Methods: this is a semi-structured, descriptive, observational, qualitative study that was performed during eight months. Focus group (FG) interviews were performed with women attending at a tertiary hospital in Brazil, who were consecutively included in the study. Seventy women with symptomatic UL were recruited to this study. FG duration was one hour with mediators with 5-6 women at each group. Collected data from discussions was processed according to thematic analysis and stored at a qualitative software. Results: women were negatively influenced by the presence of symptomatic UL. The major themes that were noticed during analysis were: beliefs and attitudes towards UL; limitation to social and professional activities; sensation of fear/unfairness/discouragement towards the symptoms and adverse effects during treatment with GnRH analogs. Conclusions: symptomatic UL has a negative impact on womens HRQL. Health providers should consider such impact when counseling women on their treatment options, since it may have an important influence in these patients’ decision-making process. While current pharmacological treatments may improve disease specific outcomes, such as bleeding intensity and tumor volume, they fail on actually improving quality of life